S&P 500 Healthcare Sector SEC Filings — July 31, 2026
The S&P 500 Healthcare sector is presenting a mixed picture for Q2 2026, characterized by strong top-line growth at major medical device and diversified pharma companies, contrasted with significant challenges in the biotech and specialty pharma segments. Stryker and Thermo Fisher delivered robust double-digit revenue growth, while AbbVie showed strong core growth driven by immunology and neuroscience, offset by continued Humira erosion. However, Moderna faces a deteriorating cash position and a failed Phase 3 trial, while Amgen disclosed a material cybersecurity breach. A key portfolio-level trend is the aggressive capital deployment for M&A and share buybacks, which is pressuring balance sheets and cash positions across the group. Insider activity was limited but negative at Intuitive Surgical, while forward-looking statements from AbbVie and Moderna point to divergent paths, with AbbVie guiding higher and Moderna struggling to stabilize. The sector is bifurcated between established growth engines and companies facing pipeline or operational headwinds.